MARK VELARDE: Open Payments
NPI 1578513560 · WESCOSVILLE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,283 in 63 payments from 18 companies in 2025. Trend: 2023 $1,698 · 2024 $1,457 · 2025 $1,283
Food & beverage: $1,213Education: $70
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $230 |
| Lilly USA, LLC | 10 | $197 |
| ABBVIE INC. | 10 | $182 |
| Astellas Pharma US Inc | 3 | $103 |
| Novo Nordisk Inc | 4 | $92 |
| PFIZER INC. | 5 | $86 |
| Exact Sciences Corporation | 3 | $72 |
| Alnylam Pharmaceuticals Inc. | 3 | $66 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $58 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $41 |
Products named: JARDIANCE, MOUNJARO, UBRELVY, QULIPTA, FARXIGA, NURTEC ODT, ONPATTRO, XIFAXAN.
Industry payments across PA — which companies pay providers there.
